Literature DB >> 22249258

Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.

S Cutrupi1, S Reineri, A Panetto, E Grosso, L Caizzi, L Ricci, O Friard, S Agati, M Scatolini, G Chiorino, A E Lykkesfeldt, M De Bortoli.   

Abstract

Pharmacological resistance is a serious threat to the clinical success of hormone therapy for breast cancer. The antiproliferative response to antagonistic drugs such as tamoxifen (Tam) critically depends on the recruitment of NCoR/SMRT corepressors to estrogen receptor alpha (ERα) bound to estrogen target genes. Under certain circumstances, as demonstrated in the case of interleukin-1β (IL-1β) treatment, the protein Tab2 interacts with ERα/NCoR and causes dismissal of NCoR from these genes, leading to loss of the antiproliferative response. In Tam-resistant (TamR) ER-positive breast cancer cells, we observed that Tab2 presents a shift in mobility on sodium dodecyl sulfate--PAGE (SDS-PAGE) similar to that seen in MCF7 wt upon stimulation with IL-1β, suggesting constitutive activation. Accordingly, TamR treatment with Tab2-specific short interfering RNA, restored the antiproliferative response to Tam in these cells. As Tab2 is known to directly interact with the N-terminal domain of ERα, we synthesized a peptide composed of a 14-aa motif of this domain, which effectively competes with ERα/Tab2 interaction in pull-down and co-immunoprecipitation experiments, fused to the carrier TAT peptide to allow internalization. Treatment of TamR cells with this peptide resulted in partial recovery of the antiproliferative response to Tam, suggesting a strategy to revert pharmacological resistance in breast cancer. Silencing of Tab2 in TamR cells by siRNA caused modulation of a gene set related to the control of cell cycle and extensively connected to BRCA1 in a functional network. These genes were able to discern two groups of patients, from a published data set of Tam-treated breast cancer profiles, with significantly different disease-free survival. Altogether, our data implicate Tab2 as a mediator of resistance to endocrine therapy and as a potential new target to reverse pharmacological resistance and potentiate antiestrogen action.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249258     DOI: 10.1038/onc.2011.627

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Identification of two novel mammographic density loci at 6Q25.1.

Authors:  Judith S Brand; Jingmei Li; Keith Humphreys; Robert Karlsson; Mikael Eriksson; Emma Ivansson; Per Hall; Kamila Czene
Journal:  Breast Cancer Res       Date:  2015-06-03       Impact factor: 6.466

2.  Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer.

Authors:  Valentina Miano; Giulio Ferrero; Stefania Reineri; Livia Caizzi; Laura Annaratone; Laura Ricci; Santina Cutrupi; Isabella Castellano; Francesca Cordero; Michele De Bortoli
Journal:  Oncotarget       Date:  2016-01-19

3.  A Novel Functional Domain of Tab2 Involved in the Interaction with Estrogen Receptor Alpha in Breast Cancer Cells.

Authors:  Stefania Reineri; Silvia Agati; Valentina Miano; Monica Sani; Paola Berchialla; Laura Ricci; Andrea Iannello; Lucia Coscujuela Tarrero; Santina Cutrupi; Michele De Bortoli
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

4.  Upregulation of microRNA-4417 and Its Target Genes Contribute to Nickel Chloride-promoted Lung Epithelial Cell Fibrogenesis and Tumorigenesis.

Authors:  Chih-Hsien Wu; Yi-Min Hsiao; Kun-Tu Yeh; Tsui-Chun Tsou; Chih-Yi Chen; Ming-Fang Wu; Jiunn-Liang Ko
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

Review 5.  Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies.

Authors:  Michael S Shawky; Hilary Martin; Honor J Hugo; Thomas Lloyd; Kara L Britt; Andrew Redfern; Erik W Thompson
Journal:  Oncotarget       Date:  2017-01-17

Review 6.  Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

Authors:  Rocío García-Becerra; Nancy Santos; Lorenza Díaz; Javier Camacho
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

7.  The molecular diversity of Luminal A breast tumors.

Authors:  Giovanni Ciriello; Rileen Sinha; Katherine A Hoadley; Anders S Jacobsen; Boris Reva; Charles M Perou; Chris Sander; Nikolaus Schultz
Journal:  Breast Cancer Res Treat       Date:  2013-10-06       Impact factor: 4.872

8.  Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.

Authors:  X Q Zheng; J P Guo; H Yang; M Kanai; L L He; Y Y Li; J M Koomen; S Minton; M Gao; X B Ren; D Coppola; J Q Cheng
Journal:  Oncogene       Date:  2013-10-28       Impact factor: 9.867

9.  Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer.

Authors:  Fangmeng Fu; Wenhui Guo; Yuxiang Lin; Bangwei Zeng; Wei Qiu; Meng Huang; Chuan Wang
Journal:  J Transl Med       Date:  2018-10-01       Impact factor: 5.531

10.  Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.

Authors:  María Del Mar Noblejas-López; Sara Morcillo-García; Cristina Nieto-Jiménez; Miriam Nuncia-Cantarero; Balázs Győrffy; Eva M Galan-Moya; Atanasio Pandiella; Alberto Ocaña
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.